Abstract 311P
Background
Endometrial cancer (EC) is the most common gynecological malignancy worldwide. Therefore, early diagnosis of EC is critical. Routine endometrial cytology has low sensitivity and specificity. If there are few endometrial cells and there are no obvious signs of atypia, knowledge of additional diagnostic criteria will help identify pathological processes in the endometrium. The aim of the study was to evaluate the diagnostic significance of serum cytokines in patients with EC and uterine myoma (UM).
Methods
The blood serum of primary patients with stage I (initial) EC (n=42) according to FIGO was studied. The mean age of patients was 37-77 years, and patients with UM (n=20) (41-59 years). The control group included 30 practically healthy female donors (23-65 years). The level of IL1RA, IL17A (Cytokin, Russia), IL1β, 2, 4, 6, 8, 10, 18, TNFα, IFNγ and MCP- 1 (VBV, Russia) in pg/ml. The results were expressed as IQRQ1-Q3. The study was carried out in accordance with the requirements of the Ethics Commission of the Institute of ME&PhC of UlSU. Statistical analysis was performed using Jamovi 1.6.5.0.
Results
A significant increase in the level of IL1RA in the blood serum of patients at stage I EC at UM (p=0.002) and relative to control (p=0.001). The concentration of circulating IL6 was significantly increased at initial EC compared with UM (p=0.044). MCP-1 in the serum of patients with UM is reduced compared with the control group (p=0.013). At stage I EC, the level of MCP-1 in serum is significantly higher compared with control (p=0.012) and UM (p=0.005). The levels of other cytokines did not show significant differences with the control group in the presented model. In a univariate logistic regression analysis for the differential diagnosis between UM and EC, statistical significance was jointly demonstrated by IL1RA and serum IL6/MCP-1 The risk of EC increases with concomitantly elevated serum levels of IL1RA and IL6 (R2=0.82, χ2=30.5, p=0.001) with a probability of 96.2% (Spec.=0.80, Sens.=0.96), as well as with simultaneously elevated levels of IL1RA and MCP-1 (R2=0.75, χ2=26.4, р=0.001) with 88.5% probability (Spec.=0.80, Sens.=0.88).
Conclusions
Evaluation of the serum level of IL1RA, IL6, MCP-1 can be used in the differential diagnosis of EC and UM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract